

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE MOVEMENTS

This announcement is issued by HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has noted the recent unusual fluctuation in price of the shares (the “**Shares**”) of the Company.

Having made reasonable enquiries with respect to the Company in the circumstances, the Company confirms that, as of the time of this announcement, it is not aware of any reasons for the recent fluctuation in price of the Shares or of any information that needs to be disclosed to avoid a false market in the Company’s securities, or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company also confirms that, as of the time of this announcement, the Group’s business operation remains normal, and that there is no material adverse change to the business operation and financial position of the Group. This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping

Executive Director and Chief Executive Officer

Hong Kong, June 24, 2024

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. Jin LI and Mr. HUNG Tak Wai as independent non-executive Directors.